Skip to content
Companies

Atomwise

AI virtual screening for small-molecule drugs

Raised to date

$64.1M

of $85M offered across 2 Form D filings

Still open
$20.9M
Investors
19
Last filed
Mar 19, 2026

About

Atomwise Inc. is a pioneering technology-enabled pharmaceutical company that employs artificial intelligence to transform the landscape of small molecule drug discovery. By leveraging advanced machine learning techniques, Atomwise aims to streamline the drug development process, making it not only more efficient but also more effective in identifying viable therapeutic candidates.

Atomwise stands out for its innovative use of AI to significantly reduce the time and cost traditionally associated with drug discovery while enhancing the likelihood of success.

Funding

$50M round, first sold Mar 2024$44.3M sold$5.7M still openMar 202420252026
Now
  • EquityFiled Mar 19, 2026Form D
    $19.8M/ $35M
  • EquityFiled Mar 14, 2025Form D
    $44.3M/ $50M

Product

AtomNet

Drug Discovery

AtomNet is an advanced AI-powered drug discovery platform that utilizes deep learning algorithms and convolutional neural networks to predict interactions between small molecules and protein targets. This cutting-edge technology enables the virtual screening of billions of chemical compounds, rapidly identifying the most promising candidates for further development.

  • Rapid virtual screening of billions of compounds
  • Predictive modeling of molecule-protein binding affinities
  • Deep learning and convolutional neural network technology

Built for

Pharmaceutical companies and biotechnology firms

People on file